Oxford’s SpyBiotech secures $4m grant
SpyBiotech, the Oxfordshire-based biotechnology company with a novel vaccine platform technology which can target infectious diseases, cancer and chronic diseases, has secured a $4,094,561 grant from the Bill & Melinda Gates Foundation.
The grant has been awarded to further develop SpyBiotech’s SpyVector platform, harnessing the firm’s “plug and display” technology to design a broadly cross-protective coronavirus vaccine.
The platform improves efficacy and boosts the capabilities of Adenovirus-based vaccines against current and future pandemic viruses.
Sumi Biswas, Ph.D., President and CSO of SpyBio, said: “This grant will showcase the potential of the SpyVector technology which can be applied to generate vaccines against a wide range of pathogens and therapeutic applications.
“Our SpyVector technology, developed by our Principal Scientist Dr. Matthew Dicks and his team, has the potential to generate more broadly protective coronavirus vaccines.”
Read more - Former Covid-19 Taskforce chief appointed chair of Oxford-based SpyBiotech
